Current Oncology Reports

, Volume 3, Issue 3, pp 271–278

Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?

  • Tarun Kewalramani
  • Craig H. Moskowitz
Article

Abstract

High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin’s disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin’s disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Tarun Kewalramani
    • 1
  • Craig H. Moskowitz
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations